Stachyose is a prebiotic, a non-reducing tetrasaccharide in the rafnose family of oligosaccharides with few side efects.

STA 2842 (STA2842) is a highly specific inhibitor of HSP90 (IC50=135 nM, HSP90α) that competitively binds the N-terminal ATP pocket of HSP90.

ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A2A receptor, with Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively.

ST-168 is a novel potent, orally available MEK/PI3K bifunctional inhibitor with IC50 of 182, 69.2, 1482, 2293, and 41.7 nM for MEK1, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively.

ST-162 is a potent, bifunctional MAPK/PI3K antagonist with IC50 of 191 nM and 398 nM for PI3Kα and MEK1, respectively.

ST-148 a novel potent, broad-spetrum inhibitor of dengue virus (DENV) replication, inhibits DENV-2 wth EC50 of 16 nM in viral titer reduction assays, interacts with the DENV Capsid protein.

SSR411298 is a highly selective, brain penetrant and orally-active inhibitor of FAAH with IC50 of 62.5 nM (mouse brain FAAH).

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SRT 2183 is a potent, selective SIRT1 activator with EC1.5 of 0.36 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol.

SRI 37892 (SRI37892) is a novel potent, small molecule Frizzled 7 (Fzd 7) inhibitor with IC50 of 0.66 uM in Wnt/β-catenin assay.

SR7826 is a potent and selective LIM kinase (LIMK) inhibitor with IC50 of 43 nM, displays >100-fold selectivity over ROCK1 and ROCK2, as well as JNK kinases (>400-fold).

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR-57227 is a high affinity, selective 5-HT3 receptor agonist, demonstrates anticonvulsant effects in vivo..

SR-3306 is a highly selective, brain penetrant, potent inhibitor of JNK with IC50 of 67, 283 and 159 nM for JNK1, JNK2 and JNK3, >100-fold selectivity over p38.

SR-16835 is a potent full agonist of ORL1 receptor (NOP receptor) with binding Ki of 11.4 nM, with low-affinity mu-opioid partial agonist activity (Ki=79.9 nM).

SR-16435 is a mixed NOP/μ-opioid partial agonist with equally high affinity (Ki=29 nM) for both NOP and μ-opioid receptors.

SR-16430 is a selective ORL1 receptor (NOP receptor) antagonist that has 10-fold selectivity over μ-opioid receptor..

SR146131 (SR-146131) a small molecule positive allosteric modulator of the type 1 cholecystokinin receptor (CCK1R) with pEC50 of 10.34..

SR-14150 is a potent NOP/μ-opioid partial agonist with Ki of 1.39 nM and 29.9 nM, respectively.

SR12460 (SR-12460) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation, inhibits TNF-α-mediated NF-κB activation with IC50 of 20.24 uM.

SR12343 (SR-12343) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation, inhibits TNF-α-mediated NF-κB activation with IC50 of 11.34 uM in luciferase assays.

SR 9444 is a small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK with IC50 of 12 nM and 99 nM respectively.

SR 16832 is a dual-site covalent antagonist of peroxisome proliferator-activated receptor γ (PPARγ).

Squalene epoxidase inhibitor. Suppresses triglyceride biosynthesis through the farnesol pathway.

SPX-101 is a specific, peptide mimetic promoter of epithelial sodium channel (ENaC) internalization, binds selectively to ENaC and promotes internalization of the α-, β-, and γ-subunits.

SPV 106 is the first mixed activator/inhibitor of Histone acetyltransferases (HATs), potentiates p300/CBP-associated factor (PCAF) HAT activity while inhibiting those of p300/CBP and recombinant CBP.

SPRi3 (SPR inhibitor 3) is a small molecule inhibitor of sepiapterin reductase (SPR) with IC50 of 74 nM in cell-free assays, efficiently reduces biopterin levels with IC50 of 5.2 uM.

SPR-00305 is a potent MvfR inhibitor and displays target engagement.

SPOP-IN-6b is a potent, small-molecule E3 Ligase adaptor SPOP (speckle-type POZ protein) inhibitor that inhibits the SPOP-substrate protein interaction with IC50 of 35 uM (inhibits puc-SBC1 peptide binding to SPOP).

SPL-707 (SPL707) is the first selective, orally active signal peptide peptidase-like 2a (SPPL2a) inhibitor with IC50 of 77 nM, shows 25-fold selectivity over γ-secretase and SPP.